17 sats \ 1 reply \ @dontforgetthekeys OP 11 Aug \ parent \ on: The Benefits of Ozempic Are Multiplying science
I'm going to dig into this one later. It read like a fluff piece for their doctors and hospitals.
the two things that stood out to me:
  • they did the study backwards: when you do that you're usually bias to find what you want to find.
  • There are several limitations to the study. Mass Eye and Ear sees an unusually high number of people with rare eye diseases, the study population is majority white, and the number of NAION cases seen over the six-year study period is relatively small. With small case numbers, statistics can change quickly, Rizzo noted. The researchers also couldn't determine if the patients actually took their medication or if they started and then stopped taking semaglutide at some point and how this might have impacted their risk.
I'm not saying they are wrong. I just want to spend more time figuring our where the correlation is and how does one get this rare NAION condition in the first place.
write
preview
42 sats \ 0 replies \ @justin_shocknet 11 Aug
Yea its not like a typical study it started off anecdotal...
MassGen is an elite facility and I wouldn't expect a marketing or a fishing expedition out of them, rather the opposite as they're adjacent to that Cambridge Biotech Capital sphere that's marketing the drugs... Maybe hospitals are being more proactive after the C19 stuff...
reply